Edition:
United States

Oramed Pharmaceuticals Inc (ORMP.OQ)

ORMP.OQ on NASDAQ Stock Exchange Capital Market

7.26USD
30 Sep 2016
Change (% chg)

$-0.04 (-0.55%)
Prev Close
$7.30
Open
$7.34
Day's High
$7.34
Day's Low
$7.23
Volume
5,834
Avg. Vol
10,164
52-wk High
$10.72
52-wk Low
$5.47

ORMP.OQ

Chart for ORMP.OQ

About

Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible... (more)

Overall

Beta: 0.57
Market Cap(Mil.): $95.37
Shares Outstanding(Mil.): 13.14
Dividend: --
Yield (%): --

Financials

  ORMP.OQ Industry Sector
P/E (TTM): -- 43.83 36.83
EPS (TTM): -0.69 -- --
ROI: -29.54 -0.29 13.93
ROE: -31.81 -2.99 14.84

BRIEF-Oramed Pharmaceuticals receives additional $4 mln milestone payment from HTIT

* Oramed receives additional $4 million milestone payment from HTIT Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Aug 02 2016

BRIEF-Oramed reports statistically significant results across key Glycemic endpoints

* Ormd-0801 did not show a significant difference in change in morning fasting serum insulin, c-peptide, or triglycerides

Jul 28 2016

BRIEF-Oramed Pharmaceuticals says unit entered into general technical agreement with Premas Biotech

* Says unit Oramed Ltd. entered into a General Technical Agreement with Premas Biotech Pvt. Ltd - SEC Filing

Jul 27 2016

BRIEF-Oramed Pharmaceuticals unit enters into service agreement with XERTECS GmbH

* On June 13, 2016, Oramed Ltd entered into a service agreement with XERTECS GmbH

Jun 16 2016

BRIEF-Oramed announces positive top-line results from phase IIb oral insulin study

* Oramed announces positive top-line results from phase iib oral insulin study

May 18 2016

BRIEF-Oramed says to announce results from Phase 2B clinical trial in about 2 weeks

* Expects to announce results from its Phase 2B clinical trial for its ORMD-0801 oral insulin capsule in about two weeks time Source text for Eikon: [(http://1.usa.gov/1SNB87n )] Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

May 04 2016

BRIEF-Oramed Pharmaceuticals receives patent term adjustment extending the term of its U.S. patent

* Receives patent term adjustment extending the term of its U.S. patent

Apr 12 2016

Earnings vs. Estimates